Physician profile
Maria Clemente
NPI 1932141108
$1,692.09
in general payments reported to CMS, 2019-2025
16 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.67 · 2020: $136 · 2021: $135 · 2022: $565 · 2023: $379 · 2024: $337 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $277.80 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $252.95 | 2023 | Tepezza, Uplizna |
| Sun Pharmaceutical Industries INC. | $229.10 | 2021-2025 | Cequa |
| Allergan, INC. | $218.35 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $189.70 | 2022 | |
| Bausch & Lomb Americas INC. | $170.75 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $150.86 | 2024 | |
| Pfizer INC. | $49.65 | 2023-2025 | |
| Alcon Vision LLC | $43.01 | 2024-2025 | Eysuvis |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Glaxosmithkline, LLC. | $17.00 | 2025 | Trelegy Ellipta |
| Kala Pharmaceuticals, INC. | $16.61 | 2019 | |
| Amgen INC. | $16.44 | 2025 | Tepezza |
| Axsome Therapeutics, INC. | $15.09 | 2025 | Symbravo |
| Coopervision INC. | $14.06 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Clemente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.